LINCOLN

Lincoln Pharmaceuticals Share Price

 

 

Invest in Lincoln Pharmaceuticals with 2.91X leverage

Invest with MTF

Performance

  • Low
  • ₹609
  • High
  • ₹654
  • 52 Week Low
  • ₹440
  • 52 Week High
  • ₹696
  • Open Price₹645
  • Previous Close₹654
  • Volume124,293
  • 50 DMA₹500.89
  • 100 DMA₹508.67
  • 200 DMA₹534.47

Investment Returns

  • Over 1 Month + 29.3%
  • Over 3 Month + 18.61%
  • Over 6 Month + 14.91%
  • Over 1 Year + 10.95%

Smart Investing Starts Here Start SIP with Lincoln Pharmaceuticals for Steady Growth!

Invest Now

Lincoln Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 14.2
  • PEG Ratio
  • -8.3
  • Market Cap Cr
  • 1,249
  • P/B Ratio
  • 1.7
  • Average True Range
  • 32.7
  • EPS
  • 43.85
  • Dividend Yield
  • 0.3
  • MACD Signal
  • 12.08
  • RSI
  • 73.65
  • MFI
  • 93.6

Lincoln Pharmaceuticals Financials

Lincoln Pharmaceuticals Technicals

EMA & SMA

Current Price
₹623.55
-30.75 (-4.7%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹519.32
  • 50 Day
  • ₹500.89
  • 100 Day
  • ₹508.67
  • 200 Day
  • ₹534.47

Resistance and Support

628.75 Pivot Speed
  • R3 694.10
  • R2 674.05
  • R1 648.80
  • S1 603.50
  • S2 583.45
  • S3 558.20

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lincoln Pharmaceuticals manufactures pharmaceutical formulations across various therapeutic segments, including antibiotics, anti-malarial, and nutraceuticals. With state-of-the-art production facilities, it serves domestic and international markets, exporting products to over 60 countries globally.

Lincoln Pharmaceuticals has an operating revenue of Rs. 651.94 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 18% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 35% and 22% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 64 which is a FAIR score but needs to improve its earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lincoln Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-07 Quarterly Results
2025-05-22 Audited Results & Final Dividend
2025-02-13 Quarterly Results
Date Purpose Remarks
2025-09-12 FINAL Rs.1.80 per share(18%)Final Dividend
View Lincoln Pharmaceuticals Dividend History Arrow

Lincoln Pharmaceuticals F&O

Lincoln Pharmaceuticals Shareholding Pattern

49.78%
0%
4.7%
36.28%
9.24%

About Lincoln Pharmaceuticals

  • NSE Symbol
  • LINCOLN
  • BSE Symbol
  • 531633
  • Managing Director
  • Mr. Mahendra G Patel
  • ISIN
  • INE405C01035

Similar Stocks to Lincoln Pharmaceuticals

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹623 As on 16 February, 2026 | 21:26

The Market Cap of Lincoln Pharmaceuticals is ₹1249 Cr As on 16 February, 2026 | 21:26

The P/E ratio of Lincoln Pharmaceuticals is 14.2 As on 16 February, 2026 | 21:26

The PB ratio of Lincoln Pharmaceuticals is 1.7 As on 16 February, 2026 | 21:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23